A placebo-controlled trial of L-365,260, a CCKB antagonist, in panic disorder.
Biol Psychiatry
; 37(7): 462-6, 1995 Apr 01.
Article
em En
| MEDLINE
| ID: mdl-7786960
ABSTRACT
The functional role of cholecystokinin in the central nervous system is unknown. The tetra peptide CCK-4 was previously observed to induce panic attacks in a majority of normal volunteers and patients with panic disorder. Furthermore, it had been demonstrated that pretreatment with 10-50 mg of L-365,260, a selective CCKB antagonist, blocked CCK-4 induced panic in patients with panic disorder. Therefore, the present multicenter, placebo-controlled, double-blind trial was designed to investigate the efficacy of L-365,260, a CCKB antagonist, in patients with panic disorder with or without agoraphobia. Following a 1-week, single-blind placebo period, 88 patients were randomized to double-blind treatment in which they received either L-365,260, 30 mg qid, or placebo for 6 weeks. At the dose tested, there were no clinically significant differences between L-365,260 and placebo in global improvement ratings, Hamilton anxiety rating scale scores, panic attack frequency, panic attack intensity, or disability measures. The possible reasons for lack of effect with L-365,260 are discussed.
Buscar no Google
Base de dados:
MEDLINE
Assunto principal:
Compostos de Fenilureia
/
Benzodiazepinonas
/
Receptores da Colecistocinina
/
Transtorno de Pânico
Tipo de estudo:
Clinical_trials
Limite:
Adult
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Ano de publicação:
1995
Tipo de documento:
Article